These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 28139570

  • 1. Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas.
    Astaf'eva LI, Kadashev BA, Shishkina LV, Kalinin PL, Fomichev DV, Kutin MA, Aref'eva IA, Dzeranova LK, Sidneva YG, Klochkova IS, Rotin DL.
    Zh Vopr Neirokhir Im N N Burdenko; 2016; 80(6):24-35. PubMed ID: 28139570
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N.
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.
    Peng G, Guo C, Lv Y, Li D, Zhou L, Shen R, Chen Y, Zheng X, Sun Z, Zheng H, Long M.
    BMC Endocr Disord; 2022 Dec 21; 22(1):325. PubMed ID: 36539773
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis and treatment of pituitary adenomas.
    Chanson P, Salenave S.
    Minerva Endocrinol; 2004 Dec 21; 29(4):241-75. PubMed ID: 15765032
    [Abstract] [Full Text] [Related]

  • 6. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM.
    Clin Endocrinol (Oxf); 1994 Mar 21; 40(3):421-8. PubMed ID: 8187308
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P.
    J Clin Endocrinol Metab; 2000 Apr 21; 85(4):1487-91. PubMed ID: 10770186
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hyperthyroidism caused by an ectopic thyrotropin-secreting tumor of the nasopharynx: a case report and review of the literature.
    Tong A, Xia W, Qi F, Jin Z, Yang D, Zhang Z, Li F, Xing X, Lian X.
    Thyroid; 2013 Sep 21; 23(9):1172-7. PubMed ID: 23402621
    [Abstract] [Full Text] [Related]

  • 10. Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study.
    Mo C, Chen H, Xu J, Guo Y, Wang Y, Li Z, Tong T, Gui S, Zhong L.
    Endocr Pract; 2024 May 21; 30(5):441-449. PubMed ID: 38307455
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. TSH-STAINING PITUITARY ADENOMAS: RARE, SILENT, AND PLURIHOROMONAL.
    Polanco Santos C, Sandouk Z, Yogi-Morren D, Prayson R, Recinos P, Kennedy L, Hamrahian AH, Pantalone KM.
    Endocr Pract; 2018 Jun 21; 24(6):580-588. PubMed ID: 29949434
    [Abstract] [Full Text] [Related]

  • 17. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P.
    Thyroid; 2015 Aug 21; 25(8):877-82. PubMed ID: 26244412
    [Abstract] [Full Text] [Related]

  • 18. Diagnosis, pathology, and management of TSH-secreting pituitary tumors. A single-center retrospective study of 20 patients from 1981 to 2014.
    Căpraru OM, Gaillard C, Vasiljevic A, Lasolle H, Borson-Chazot F, Raverot V, Jouanneau E, Trouillas J, Raverot G.
    Ann Endocrinol (Paris); 2019 Sep 21; 80(4):216-224. PubMed ID: 31400861
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
    Zhang CF, Liang D, Zhong LY.
    Chin Med J (Engl); 2012 Aug 21; 125(15):2758-63. PubMed ID: 22931988
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.